Team

Claudia Harper, D.V.M., is the SVP of Nonclinical Development at Recludix Pharma and has 20 years experience in preclinical research and development working on traditional and novel therapies. Most recently, she was SVP of Preclinical Development at Orna Therapeutics and built from the ground up the Comparative Medicine, Toxicology, Bioanalytical and DMPK functions, developing a circular RNA and LNP platform delivering anti-CD19 CAR targeting B-cell lymphoma. She previously served as VP of Preclinical Development and build the nonclinical functions supporting AVROBIO’s autologous ex vivo LVV transduced CD34+ HSC gene therapy platform, supporting Pompe, Hunter, and Cystinosis IND-enabling activities including the first U.S. Phase 1/2 cystinosis clinical trial which was sold to Novartis in 2023. At Biogen, she was a program team toxicologist responsible for the strategy, design and execution of IND-enabling nonclinical studies on program-specific assets. She was the first program team toxicologist on BIIB073, leading to Biogen’s Hemophilia spinoff Bioverativ (BIVV001) which was acquired by Sanofi and received FDA approval in 2023 (ALTUVIIIO®). Prior to transitioning into preclinical safety, Dr. Harper held leadership roles of increasing responsibility at Biogen Idec and Amgen as Site Head and Attending Veterinarian accountable for their respective Comparative Medicine Departments in Cambridge, MA. She holds a Doctor of Veterinary Medicine (DVM) degree from Tufts University, a Postdoctoral Associate in Biomedical Research from the Division of Comparative Medicine at Massachusetts Institute of Technology, and she is a Diplomate of the American College of Laboratory Medicine (DACLAM) as well as a Diplomate of the American Boards of Toxicology (DABT). She co-founded the Zebrafish Husbandry Association which has become an international entity, and she has authored several books and book chapters.